Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study

BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading to frequent drug discontinuations. Whereas an exposure/safety relationship was demonstrated for this drug, an exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., Albiges, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645912/
https://www.ncbi.nlm.nih.gov/pubmed/34864351
http://dx.doi.org/10.1016/j.esmoop.2021.100312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645912/
https://www.ncbi.nlm.nih.gov/pubmed/34864351
http://dx.doi.org/10.1016/j.esmoop.2021.100312

Ejemplares similares